Standardized pathology report for breast cancer
Open Access
- 1 January 2021
- journal article
- review article
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 55 (1), 1-15
- https://doi.org/10.4132/jptm.2020.11.20
Abstract
Given the recent advances in management and understanding of breast cancer, a standardized pathology report reflecting these changes is critical. To meet this need, the Breast Pathology Study Group of the Korean Society of Pathologists has developed a standardized pathology reporting format for breast cancer, consisting of 'standard data elements,' 'conditional data elements,' and a biomarker report form. The 'standard data elements' consist of the basic pathologic features used for prognostication, while other factors related to prognosis or diagnosis are described in the 'conditional data elements.' In addition to standard data elements, all recommended issues are also presented. We expect that this standardized pathology report for breast cancer will improve diagnostic concordance and communication between pathologists and clinicians, as well as between pathologists inter-institutionally.This publication has 53 references indexed in Scilit:
- Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical reviewBreast Cancer Research and Treatment, 2011
- Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working GroupJNCI Journal of the National Cancer Institute, 2011
- Validation of a Novel Staging System for Disease-Specific Survival in Patients With Breast Cancer Treated With Neoadjuvant ChemotherapyJournal of Clinical Oncology, 2011
- Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified?Breast Cancer Research and Treatment, 2010
- Ki67 in breast cancer: prognostic and predictive potentialThe Lancet Oncology, 2010
- Ki67 Expression and Docetaxel Efficacy in Patients With Estrogen Receptor–Positive Breast CancerJournal of Clinical Oncology, 2009
- Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With LetrozoleJournal of Clinical Oncology, 2008
- Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With DocetaxelJournal of Clinical Oncology, 2002
- Lymphocyte infiltrates as a prognostic variable in female breast cancerEuropean Journal of Cancer, 1992
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991